- In May 2024, Inocras entered into an agreement with IMBdx to enhance cancer patient care in the U.S. by integrating advanced diagnostic technologies, including whole-genome sequencing and liquid biopsy. This collaboration aims to leverage cutting-edge genomic insights for more precise cancer diagnosis and management. The initiative underscores the increasing significance of comprehensive genomic profiling in personalized oncology, contributing to more targeted and effective treatment strategies in the point-of-care biopsy market
- In May 2024, Karius, a genomic diagnostics company, successfully raised USD 100 million in a Series C funding round. This significant investment will likely fuel further research and development in their genomic diagnostic platforms, which have implications for rapid, point-of-care infectious disease detection and potentially non-invasive diagnostic approaches that complement biopsy. The funding highlights investor confidence in advanced genomic technologies for accelerating diagnostics in clinical settings
- In April 2024, NewBiologix SA, a technology innovation company, introduced a next-generation sequencing (NGS) and optical mapping platform. This innovative suite of technologies offers comprehensive genomic analysis services, directly impacting the capabilities of liquid biopsy by improving sensitivity, specificity, and scalability. Such advancements in sequencing platforms are crucial for the development of more accurate and accessible point-of-care liquid biopsy solutions, propelling the market's growth
- In April 2024, ANGLE plc (U.K.) and AstraZeneca ANGLE announced a second contract with AstraZeneca, initially valued at GBP 550,000, for the development of a circulating tumor cell (CTC)-based Androgen Receptor (AR) assay. This project commenced in June 2024 and successfully completed assay development by March 2025. This collaboration underscores the increasing integration of liquid biopsy technologies, particularly CTC analysis, into pharmaceutical research and clinical trials for targeted therapy development in prostate cancer, enhancing non-invasive monitoring capabilities
- In November 2023, Yourgene Health (a Novacyt subsidiary) and Laboriad (Morocco) Yourgene Health partnered with Laboriad to launch Morocco's first non-invasive prenatal testing (NIPT) platform. While not a "biopsy" in the traditional sense, NIPT is a form of liquid biopsy that analyzes cell-free fetal DNA from maternal blood, offering a non-invasive alternative for detecting genetic disorders. This initiative expands access to advanced prenatal screening at the point of care, demonstrating the broader adoption of non-invasive molecular diagnostic solutions
